Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 17/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082326 | 0.95 | SLC6A9 (0.67) | SLC6A9KCNH2GPR119CYP2C9 | |
| SCHEMBL3084991 | 0.90 | SLC6A9 (0.57) | SLC6A9KCNH2GPR119CYP2C9 | |
| SCHEMBL4867123 | 0.85 | SLC6A9 (0.53) | SLC6A9KCNH2GPR119CYP2C9 | |
| SCHEMBL4424473 | 0.84 | SLC6A9 (1.00) | SLC6A9KCNH2 | |
| SCHEMBL3080170 | 0.82 | SLC6A9 (0.65) | SLC6A9KCNH2 | |
| SCHEMBL3079674 | 0.82 | SLC6A9 (0.61) | SLC6A9KCNH2 | |
| SCHEMBL3085218 | 0.81 | SLC6A9 (0.50) | SLC6A9KCNH2GPR119CYP2C9 | |
| SCHEMBL3082386 | 0.81 | SLC6A9 (0.59) | SLC6A9KCNH2 | |
| SCHEMBL3084130 | 0.80 | SLC6A9 (0.56) | SLC6A9KCNH2GPR119 | |
| SCHEMBL4422118 | 0.80 | SLC6A9 (0.76) | SLC6A9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1843767-B1 | 2,5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS. | HOFFMANN LA ROCHE (CH) | 2009-07-08 | — | — | EP | claimed |
| JP-2008527016-A | — | — | 2008-07-24 | — | — | JP | claimed |
| EP-1843767-A1 | 2,5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS. | F. Hoffmann-Roche AG (CH) | 2007-10-17 | — | — | EP | claimed |
| WO-2006077026-A1 | 2, 5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-I) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRY DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | claimed |
| US-20060160788-A1 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | claimed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1843767-B1 | 2,5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS. | HOFFMANN LA ROCHE (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20060160788-A1 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160788-A1 | Substituted phenyl methanone derivatives | SLC6A5, SLC6A1, SLC1A1 | SLC6A9 18/4885KCNH2 1806/4885GPR119 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.